Titlebook: Contemporary Pharmacotherapy of Overactive Bladder; Lindsey Cox,Eric S. Rovner Book 2019 Springer Nature Switzerland AG 2019 voiding dysfu

concise

Intravesical Chemodenervation and Toxins,ts fail. Intravesical therapy with botulinum neurotoxin should be introduced as a third-line treatment option in those OAB patients refractory to oral therapy or intolerant to its systemic side effects. The popularity of intravesical therapy with botulinum toxin has continuously increased due to the

他很靈活

iodides

BROW

Considerations in Pediatric Overactive Bladder,urologic abnormality. This troublesome condition has a prevalence of as high as 15–20% of the pediatric population, with 2–4% of 7-year-old children reporting incontinence episodes at least once a week. The main objectives of treatment are to normalize the micturition pattern, bladder and pelvic flo

Fsh238

障礙

Considerations in the Medically Complex and Frail Elderly,h significant adverse consequences in terms of quality of life and health outcomes. OAB management in this group of patients requires the treating clinician to take a broader view of the condition and its effect on the patient. The underlying physiological change in the lower urinary tract, coupled

音樂(lè)會(huì)

Individualizing Drug Therapy,linergic drugs and β3-agonists (mirabegron). Both classes of medications are effective in controlling the symptoms associated with OAB; however, they may produce side effects that may limit successful therapy. Successful therapy is dependent upon patient’s compliance, and thus individualizing drug t

LAY

Quality Assessment in View of System Theory, that is expeditious, easy to understand, complete, and provides a thorough assessment of the patient satisfaction or outcome. Providers may consider utilizing shared decision-making to set realistic expectations and choose a practical outcome measure specific to one’s clinical practice to optimize patient care and satisfaction.

electrolyte

Conquest

Visas in international and municipal laws,ids (capsaicin and resiniferatoxin) are also an available therapeutic option, they are not regularly utilized due to their lack of FDA approval and documented efficacy and safety. The aim of this chapter is to describe the clinical applications of injectable intravesical agents for OAB and discuss their mechanism of action, outcomes, and safety.